Intellia Therapeutics, Inc.
NTLA
Positions held
Your positionsNTLA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Intellia Therapeutics is positioned in the rapidly evolving biotechnology sector, focusing on innovative gene-editing therapies that could revolutionize treatment for genetic diseases.
- The company's market capitalization stands at approximately $1.73 billion, indicating a solid investor interest despite current challenges.
- Analysts have a 'buy' recommendation for NTLA, with a target mean price of $23.11, suggesting potential upside from current levels.
- Intellia has faced significant revenue declines, with a 49% drop in revenue from the prior quarter, falling to $7.7 million.
- The operating margin has deteriorated to -1472.3%, reflecting ongoing financial struggles and operational inefficiencies.
- In 2023, the company reported a net income loss of $481.192 million, highlighting the challenges it faces in achieving profitability.
Fundamentals
| Market cap | $1.77B | Enterprise value | $1.40B | Trailing P/E | — | Forward P/E | -4.91 |
| PEG | — | Price / book | 2.42 | Beta | 1.80 | Dividend yield | 0.00% |
| Revenue growth | -46.2% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -14.7% |
| Profit margin | 0.0% | ROE | -55.4% | ROA | -30.1% | Debt / equity | 0.10 |
| Current ratio | 6.65 | Free cash flow | -$249.83M | Analyst recommendation | buy | Mean target | $23.11 |
| 52w high | $28.25 | 52w low | $7.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $7.7M | $15.0M | $23.0M | $13.8M | $14.2M |
| Op margin | -1472.3% | -668.1% | -428.9% | -808.9% | -772.2% |
| Net income | -$107M | -$96.2M | -$95.8M | -$101M | -$101M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$113M | -$101M | -$98.7M | -$111M | -$110M |
- Revenue -49% vs prior quarter ($7.7M vs $15M).
- Operating margin compressed to -1472.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M |
| Op margin | -651.7% | -923.1% | -1420.5% | -879.0% |
| Net income | -$413M | -$519M | -$481M | -$474M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$441M | -$534M | -$515M | -$458M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Why Cathie Wood Is Taking Profits on AMD Stock
2026-10-06 · Nike downgraded, Home Depot initiated: Wall Street's top analyst calls
2026-10-06 · Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
2026-10-06 · Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target
2026-10-05 · Cathie Wood Just Sold $111 Million of AMD--and Loaded Up on Nvidia
2026-10-05 · Cathie Wood Reworks Major Nvidia-AMD Position
2026-10-02 · Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-29 · Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
2026-09-27 · Could This Cathie Wood Stock Soar in 2027?
2026-09-24 · Anthropic AI Discovery Gene-Editing Stocks Falling
2026-09-23 · CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
2026-09-23 · CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
Price (daily)
Full chart · RSI · MACD · patterns